NASDAQ:LYEL | Free Cash Flow | Lyell Immunopharma, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2019-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$38.51M$89,000.00-$38.6M
2025-12-31-$32.25M$304,000.00-$32.56M
2025-03-31-$54.74M$246,000.00-$54.98M
2024-12-31-$47.24M$44,000.00-$47.29M
2024-03-31-$42.02M$30,000.00-$42.05M
2023-12-31-$40.64M$25,000.00-$40.66M
2023-03-31-$46.21M$1.53M-$47.75M
2022-12-31-$40.27M$4.58M-$44.85M
2022-03-31-$47.85M$9.73M-$57.59M
2021-12-31-$33.21M$10.27M-$43.48M
2021-03-31-$33.6M$19.19M-$52.79M
2020-12-31-$26.73M$24.88M-$51.61M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$150.02M$780,000.00-$150.8M
2024-12-31-$162.39M$464,000.00-$162.86M
2023-12-31-$163.69M$2.69M-$166.38M
2022-12-31-$169.56M$24.28M-$193.83M
2021-12-31-$126.25M$65.5M-$191.75M
2020-12-31-$160.87M$51.48M-$212.36M
2019-12-31$39.47M$16.05M$23.43M